Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
about
Targeted radionuclide therapies for pancreatic cancerTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyThe development of immunoconjugates for targeted cancer therapyMechanisms of action of therapeutic antibodies for cancerThe safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cellsRadiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Pretargeted molecular imaging and radioimmunotherapy.Trop2: from development to disease.Radioimmunotherapy--a potential novel tool for pancreatic cancer therapy?Site-specific chemical modification of antibody fragments using traceless cleavable linkers.Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculatureADME for Therapeutic Biologics: Antibody-Derived Proteins and Proteins with Novel Scaffolds
P2860
Q26801364-5031A109-4242-4A39-B9A6-5513910D2DACQ26993238-0AACFF17-67E4-4AB3-B8E4-77A8E29ED7F2Q27021990-1632D986-8AA3-44CC-8EE3-BE71DB4FA335Q28385366-1D45FF96-5876-4420-968F-CB5F57374064Q35161396-BD6F7EF0-7BBF-4456-9DA2-2D69E49FDA64Q35629379-C71C53FD-AE1E-422A-9969-45DF9E9FD0B4Q36347760-B02DE880-0341-4506-9E4C-2114EC63BF04Q37323292-BD7FECAE-C012-45EF-8BD2-B9BB4C689507Q38014920-E2F3FC62-C038-4E4F-ADF8-04D7DEE1E064Q38017203-B0E2F558-BB27-4471-985F-AEB410A2E302Q38022016-53AAE9CF-5485-4487-B8AA-1A0F4352913EQ38293559-A0CC3EAC-67D0-4340-BF00-7A794BA738D2Q38450531-C80EA2D0-6D8D-4216-865B-9B59DB8B0B81Q44829143-2338B4B9-DE32-4695-9032-BDDC1362204BQ47143718-44EB6434-7047-46C1-8880-6E3ABF165274Q50138482-C11C7329-48ED-4E79-AA8D-BFEF97CDA4A1Q51740406-60ED5B10-D42E-438D-B3C2-F627C991B1A1Q57911963-646C6CBD-993C-4E9E-A1D0-4199980E79A3Q58869554-22C7DCDC-E5C6-4BEF-B3E6-4519DA54DAD0
P2860
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@en
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@nl
type
label
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@en
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@nl
prefLabel
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@en
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@nl
P2093
P2860
P1476
Combination radioimmunotherapy ...... ic carcinoma xenograft models.
@en
P2093
David M Goldenberg
Habibe Karacay
Robert M Sharkey
Serengulam V Govindan
P2860
P304
P356
10.1158/1535-7163.MCT-11-0115
P577
2011-04-05T00:00:00Z